Sorrento Announces That Its Subsidiary Levena and Its Partner Escugen Have Received Clearance to Begin Clinical Trials With Anti-TROP-2 Antibody Drug Conjugate For Multiple Solid Tumors

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence